Výnosy R/R společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Výnosy R/R společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Výnosy R/R společnosti Aerie Pharmaceuticals Inc je 105.41%
Jaká je definice metriky Výnosy R/R?
Roční růst tržeb za poslední 3 roky (Revenue Y/Y) představuje růst tržeb z roku na rok zprůměrovaný za poslední 3 roky.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Výnosy R/R společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou výnosy r/r podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Výnosy R/R společnosti RWE AG je 105.22%
- Hodnota metriky Výnosy R/R společnosti United Airlines je 105.23%
- Hodnota metriky Výnosy R/R společnosti United Continental je 105.23%
- Hodnota metriky Výnosy R/R společnosti JinkoSolar Co. Ltd je 105.27%
- Hodnota metriky Výnosy R/R společnosti The Fulham Shore PLC je 105.29%
- Hodnota metriky Výnosy R/R společnosti Bonanza Creek Inc je 105.34%
- Hodnota metriky Výnosy R/R společnosti Aerie Pharmaceuticals Inc je 105.41%
- Hodnota metriky Výnosy R/R společnosti Oakley Capital Investments je 105.46%
- Hodnota metriky Výnosy R/R společnosti Despegar.com Corp je 105.53%
- Hodnota metriky Výnosy R/R společnosti Eni S.p.A je 105.75%
- Hodnota metriky Výnosy R/R společnosti Emkay Global Services je 105.77%
- Hodnota metriky Výnosy R/R společnosti Panoro ASA je 105.89%
- Hodnota metriky Výnosy R/R společnosti Orbit Exports je 106.40%